Development of simultaneous detection of total prostate-specific antigen (tPSA) and free PSA with rapid bead-based immunoassay.
OBJECTIVE
Prostate-specific antigen (PSA) is the most important biochemical tumor marker for the early detection of prostate cancer; however, its diagnostic specificity is low. Therefore, free PSA (fPSA) test is recommended as an adjunct to increase the specificity. However, all the current technology only allows detecting one biomarker at one time. In this study, we reported a flexible bead-based immunoassay to measure total PSA (tPSA) and fPSA simultaneously.


METHODS
We used the Luminex xMAP bead array technology to measure tPSA and fPSA at one time, employing two mouse monoclonal anti-PSA antibodies (5G6 and 8A6) for coating and another mouse monoclonal anti-PSA antibody (5A6) for detection. Then we compared the data of Luminex assay with that of the conventional enzyme-linked immunosorbent assay (ELISA).


RESULTS
The assay was fast with a wide dynamic range. The lower detection limit for tPSA and fPSA were 2.3 and 1.3  pg/ml. The inter-assay coefficients for tPSA and fPSA were between 5.64 and 7.65%, and the intra-assay coefficients for tPSA and fPSA were between 4.15 and 5.89%. A close correlation between the new assay and the conventional ELISA was observed.


CONCLUSIONS
The bead-based platform is rapid, sensitive, and less expensive, which allows both single sample and high-throughput measurement of tPSA and fPSA over a wide range of concentrations.
Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.
Chong
C
Xie
Guomin
G
Wang
D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor / Q000097:blood* / Q000378:metabolism; D055088:Early Detection of Cancer / Q000379:methods*; D015200:Fluoroimmunoassay / Q000191:economics / Q000379:methods; D006801:Humans; D057230:Limit of Detection; D008297:Male; D008863:Microspheres; D017430:Prostate-Specific Antigen / Q000097:blood* / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis*; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity
D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen
Hum Immunol. 2010 Jan;71(1):45-9
19808074
J Immunol Methods. 2006 Feb 20;309(1-2):200-4
16406059
J Urol. 2003 Nov;170(5):1787-91
14532777
Urol Int. 2006;76(1):27-30
16401917
Urology. 2001 Jun;57(6):1105-11
11377319
Br J Cancer. 2010 Feb 2;102(3):469-74
20051951
Prostate. 2003 Jul 1;56(2):131-41
12746838
Biosens Bioelectron. 2009 Oct 15;25(2):332-7
19665363
Urology. 1999 Apr;53(4):736-45
10197849
Int J Urol. 2005 Apr;12(4):346-52
15948720
Jpn J Clin Oncol. 1999 Jun;29(6):303-7
10418560
Hum Immunol. 2009 Jul;70(7):496-501
19364516
World J Urol. 2009 Oct;27(5):581-5
19562347
J Urol. 1998 Sep;160(3 Pt 1):870-5
9720579
BJU Int. 2004 Jul;94(1):47-50
15217429
Electrophoresis. 2009 Dec;30(23):4008-19
19960465
Clin Chem. 1993 Dec;39(12):2483-91
7504592
BJU Int. 1999 Dec;84(9):1021-7
10571627
Biosens Bioelectron. 2009 Apr 15;24(8):2678-83
19261459
BJU Int. 2000 Apr;85(6):708-14
10759671
Eur Urol. 2000 Oct;38(4):380-7
11025374